Objectives X-ray iodinated contrast media have been shown to generate contrast in MR images when used with the chemical exchange saturation transfer (CEST) approach. The aim of this study is to compare contrast enhancement (CE) capabilities and perfusion estimates between radiographic molecules and a Gd-based contrast agent in two tumour murine models with different vascularization patterns. Methods MRI-CEST and MRI-CE T 1w images were acquired in murine TS/A and 4 T1 breast tumours upon sequential i.v. injection of iodinated contrast media (iodixanol, iohexol, and iopamidol) and of gadoteridol. The signal enhancements observed in the two acquisition modalities were evaluated using Pearson's correlation, and the correspondence in the spatial distribution was assessed by a voxelwise comparison. Results A significant, positive correlation was observed between iodinated contrast media and gadoteridol for tumour contrast enhancement and perfusion values for both tumour models (r = 0.51-0.62). High spatial correlations were observed in perfusion maps between iodinated molecules and gadoteridol (r = 0.68-0.86). Tumour parametric maps derived by iodinated contrast media and gadoteridol showed high spatial similarities. Conclusions A good to strong spatial correlation between tumour perfusion parameters derived from MRI-CEST and MRI-CE modalities indicates that the two procedures provide similar information. Key Points • Gd-based agents are the standard of reference for contrastenhanced MRI.
Introduction
Currently, contrast-enhanced (CE) studies are an essential tool for radiologists, especially for applications in oncology, either Electronic supplementary material The online version of this article (doi:10.1007/s00330-016-4552-7) contains supplementary material, which is available to authorized users. when using Gd-based agents within the MRI-CE approach, or upon the administration of iodinated radiographic agents for CT examinations [1] [2] [3] [4] [5] [6] .
However, in the past decade, serious clinical issues questioned the safety profiles of Gd-based contrast agents (CAs). The first issue linked the occurrence of nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment to the administration of a Gd-based CA, resulting in a black-box warning on their use by FDA [7] [8] [9] . Gd complexes with low thermodynamic/kinetic stability have been associated with this risk [10, 11] . More recently, a new concern has been raised upon signal hyperintensities observed in specific brain regions, surmising a possible long-term Gd deposition. However, no evidence for any clinical effect associated with Gd retention in the brain has been proven [12] [13] [14] .
As a consequence, despite the availability of Gd-based agents endowed with high stability and contrast efficiency (higher relaxivity), there is an increasing issue among manufacturers to seek possible replacement of these contrast agents. On this basis, it seems straightforward to search for alternatives in the field of iodinated contrast media currently used for the CT imaging modality [15] . In fact, both iodinated X-ray and gadolinium chelate CAs share similar physiochemical properties and simple two-compartment pharmacokinetics biodistribution [16] . After injection into the intravascular space, being small molecules, they leak rapidly out into the extravascular extracellular space. In addition, these agents are not metabolized and are excreted unchanged by passive glomerular filtration. As a consequence, the contrast kinetics for standard Gd-based MRI and iodinated CT contrast media are similar, and theoretically both methods should give comparable results. However, the main challenge for the CT modality is the high doses of ionizing radiation required for providing sufficient spatial and temporal resolution for accurate tumour characterization, making it difficult to use repeatedly for treatment response monitoring. These limitations could be likely overcome if using the same radiographic molecules, but within the MRI modality. This approach has been recently demonstrated with the iodinated X-ray agent iopamidol that can be detected using the chemical exchange saturation transfer (CEST) technique [17] [18] [19] [20] [21] , both at preclinical level [22, 23] and in a human volunteer with a 3 T MR scanner [24] . In addition, several other radiographic molecules have been successfully shown to provide similar contrast enhancement information within the MRI-CEST technique to that commonly provided with the CT modality [25] . CEST-MRI has been proposed as a novel approach for several applications at clinical level [26] [27] [28] [29] [30] [31] . A significant advantage of these agents through the CEST technique, in comparison to the CT modality and to Gd-based agents, relies on their capability to provide, in addition to tissue vascular characterization, accurate in vivo pH mapping in different tissues and pathological models [32] [33] [34] [35] [36] .
The aim of this work was to determine whether the contrast enhancement capabilities and perfusion estimates generated from three iodinated contrast media (two non-ionic monomers: iohexol and iopamidol; one non-ionic dimer: iodixanol) are comparable with those provided with a Gd-based contrast agent, gadoteridol, acquired in the same tumour bearing mice upon sequential injection. Furthermore, correlation of contrast enhancements and perfusion estimates between MRI-CEST and MRI-CE images was assessed both as mean estimates in tumour regions and through a direct spatial (voxelwise) comparison of the obtained parametric images in two tumour models with different vascularization patterns. 
Methods

Animal studies
All animal procedures and husbandry were performed in accordance with our university's ethical committee and European guidelines under directive 2010/63. Male and female BALB/C mice (Charles River Laboratories Italia S.r.l., Calco, Italy) were 8 to 10 weeks of age, and their weights were 22 to 28 g. Subcutaneous inoculations of 2.5 × 10 5 TS/A cells (HER2 positive breast adenocarcinoma) or 4.0 × 10 4 4T1 cells were made into both flanks of BALB/c mice. For the TS/A group, 33 mice (n = 11 mice for each investigated iodinated molecules) were used, for a total of 63 tumours (three tumours did not grow). For the 4T1 group, 30 mice (n = 10 mice for each investigated iodinated molecules) were used, for a total of 60 tumours. Mice received the same dose of iodinated contrast media of 4 g iodine/kg body weight, followed 30 min later by a 0.1 mmol Gd/kg body weight injection of gadoteridol, slowly injected via the same catheter without removing the animal from the MRI scanner.
In vivo MR imaging
MR images were acquired on a Bruker Avance 7 T MRI scanner (Bruker BioSpin MRI Ettlingen, Germany) equipped with a micro 2.5 MICWB 30 mm quadrature (1H) imaging probe. Mice were anesthetized by injecting a mixture of xylazine 5 mg/kg (Rompun, Bayer, Milan, Italy) and tiletamine/zolazepam 20 mg/kg (Zoletil 100, Virbac, Milan, Italy). Respiratory rate was continuously monitored using a respiratory air pillow (SA Instruments, Stony Brook, NY, USA).
After acquisition of scout images and of a T 2 -weighted anatomical reference image, Z-spectra before and after iodinated contrast media injection were acquired in the frequency offset range ±10 ppm using a single-shot RARE sequence with centric encoding (typical setting TR/TE/NEX = 6.0 s/ 2.7 ms/1) preceded by a 3μT cw block presaturation pulse for 5 s and by a fat-suppression module. We used an acquisition matrix of 96 × 96 for a field of view of 3 × 3 cm (in-plane spatial resolution = 312.5 μm) with a slice thickness of 1.5 mm. Thirty minutes after the last Z-spectrum acquisition, T 1 -weighted images before and after gadoteridol injection were acquired using an axial 2D fast low angle shot (FLASH) gradient echo sequence (TR 70 ms; TE 1.5 ms; flip angle 45°; slice thickness 1.5 mm; FOV 30 mm; matrix 96 × 96; 50 averages) keeping the same geometry, orientation, and spatial resolution of the CEST images.
Data analysis
All MRI-CEST and T 1w images were analyzed using homemade scripts implemented in MATLAB (The Mathworks, Inc., Natick, MA, USA). The Z-spectra were interpolated, on a voxel-by-voxel basis, by smoothing splines, B 0 -shift corrected and saturation transfer efficiency (ST%) was measured by punctual analysis [37] . For in vivo images, difference contrast maps (ΔST%) were calculated by subtracting the ST contrast observed after iodinated contrast media injection from the ST contrast observed before the injection on a per voxel basis in order to reduce the confounding effect of the endogenous CEST contributions.
T 1w images were analyzed on a voxel-by-voxel basis and signal intensities enhancement (SIenh%) was measured between pre-and post-injection of gadoteridol.
The extravasation fraction (perfusion) estimates were calculated for each agent as the percentage of pixels showing a ΔST% or a SIenh% above the threshold (3 % and 30 % for CEST and T 1w images, respectively) in the manually-defined tumour region of interest (ROI) [38] .
Reproducibility study
For reproducibility studies, a group of TS/A tumour bearing mice (n = 8) were imaged in two consecutive days following administration of iopamidol or of gadoteridol. Contrast enhancement and extravasation fraction estimates obtained by iopamidol or by gadoteridol were compared.
Statistical analysis
All results were expressed as mean ± standard deviation (SD). The statistical significance of the differences between the means of contrast enhancement and perfusion values was calculated using one-way ANOVA followed by the Bonferroni post hoc test. The Pearson's correlation coefficient (r) between the mean values in the tumour ROIs was calculated to assess the relationship between the obtained CEST and Gd-based estimates and reported with the 95 % confidence intervals (CI). Correlations were considered low when 0.3 < r < 0.5, moderate when 0.5 < r < 0.7 and strong when 0.7 < r < 1 [39] . Intermethod agreement between CEST-and Gdbased estimates was further examined by using BlandAltman analysis.
Voxelwise spatial correlation between enhanced images and between extravasation parametric maps obtained from CEST and Gd-based images were measured in tumour ROIs by calculating the two-dimensional correlation coefficient in the same tumour slice. The percentage of spatial similarity between extravasation fraction images was calculated in tumour ROIs by counting pixels where both contrast agents have been detected above their respective threshold. Spatial similarity maps have been colour-coded as follows: pixels where both contrast agents have been detected as blue pixels, pixels in which only CEST contrast agent was detected as red pixels, and pixels where only Gd-based contrast agent was detected as green pixels. Spatial correlation estimates are reported as mean ± SD.
The calculations were performed with GraphPad Prism (GraphPad Software, La Jolla, CA, USA).
For test-retest reliability experiment, intraclass correlation (ICC) coefficient along with 95 % confident interval was computed. P-values less than 0.05 were considered statistically significant. Figure S1 shows contrast enhancement and extravasation fraction values in test-retest experiment following iopamidol or gadoteridol injection. High ICC coefficients were observed for contrast enhancement values upon iopamidol or gadoteridol injections (0.80 and 0.78 for iopamidol and gadoteridol, respectively). Similar agreement were also observed for the extravasation fraction estimates (ICC = 0.73 and 0.74 for iopamidol and gadoteridol, respectively).
Results
Reproducibility of CEST and T 1w -CE imaging
Comparison of tumour perfusion assessment in the TS/A tumour model
In all tumour bearing mice, contrast enhancements upon i.v. injection of the investigated iodinated molecules were successfully observed. Figure 1 shows representative whole tumour ROI Z-spectra for the CEST iodinated molecules before and after the injection in the TS/A tumour model. A marked increase of the CEST saturation transfer effect (ST) is visible within the tumour region, upon the injection, for all the investigated X-ray molecules from the baseline ST curves.
The gadoteridol dose was administered 30 min after the acquisition of CEST-iodinated scans using the same catheter and without removing the animal from the scanner to maintain the same position in order to proceed with the subsequent voxelwise comparison of the CEST and Gd-based CA-derived parameters.
The three iodinated contrast media showed significant variability in the observed enhancement values in the corresponding MRI-CEST images. The mean CEST contrast enhancement (ΔST%) measured inside the tumour ROIs were 4.4 ± 0.2, 5.5 ± 0.4, and 6.4 ± 0.2 for iodixanol, iohexol, and iopamidol, respectively (Fig. 2a) , with significant differences between iodixanol and iopamidol (P < 0.001). Conversely, the mean contrast enhancements upon gadoteridol injection (ΔSI%) were similar for all the investigated tumours, with an overall average value of 62 ± 5 % (Fig. 2b) .
The mean extravasation fractions measured as the percentage of voxels where contrast agent detection was above the threshold were 0.61 ± 0.02, 0.73 ± 0.03, and 0.79 ± 0.02 for iodixanol, iohexol, and iopamidol, respectively (Fig. 2c) . The mean perfusion values measured upon gadoteridol injection were in the range 0.79 to 0.89, not statistically significant between the three sets of animals (as grouped on the basis of the administered iodinated molecules, Fig. 2d) . Figure 3 shows the scatterplot of the CEST-iodinated derived parameters versus CE-gadoteridol derived parameters for the 63 matched tumours. The correlation of the mean parameters between the two imaging approaches were moderate for contrast enhancement (r = 0.51, CI: 0.30-0.67, Fig. 3a) and perfusion (r = 0.62, CI: 0.42-0.74, Fig. 3b ), respectively.
In Bland-Altman analysis (Fig. 3c) CEST method underestimated the extravasation fraction by a mean of −0.2 with a lower limit of −0.48 (−1.96SD) and an upper limit of 0.12 (1.96SD). Representative parametric maps for the three investigated iodinated molecules are shown in Fig. 4 , as CEST contrast enhancement maps (Fig. 4a) and T 1w -gadoteridol enhancement maps (Fig. 4b) , respectively, superimposed onto the anatomical image. Corresponding T 1w contrast enhanced images acquired after gadoteridol injection are shown in (Fig. 5a ). Iopamidol showed a higher spatial correlation for the enhancement maps with gadoteridol in comparison to iodixanol.
The spatial correlation of the extravasation maps between iodinated and gadoteridol molecules was also strong, with mean values of 0.68 ± 0.08, 0.80 ± 0.09, and 0.86 ± 0.05 for iodixanol, iohexol, and iopamidol, respectively (Fig. 5b) . Figure 5c shows the percentage of spatial equivalence (similarity index), calculated as the number of pixels where both contrast agents have been detected. A much higher similarity index for iopamidol and iohexol (similarity mean values of 0.64 ± 0.10 and 0.76 ± 0.16, respectively), in comparison to iodixanol (0.47 ± 0.08) was observed. Representative similarity maps with colour-coded pixels are shown in Fig. 4c . For both iopamidol and iohexol in almost all voxels both the iodinated and the gadoteridol molecules have been detected.
Comparison of tumour perfusion assessment in the 4T1 tumour model
In the 4T1 tumour model similar contrast enhancement values were observed in comparison to the TS/A tumour model. The mean CEST contrast enhancement (ΔST%) measured inside the tumour ROIs were 4.0 ± 0.2, 4.8 ± 0.2, and 5.8 ± 0.3 for iodixanol, iohexol, and iopamidol, respectively (Fig. S3a) . Also, mean contrast enhancement values upon gadoteridol injection (ΔSI%) were similar for all the investigated tumours, with an overall average value of 68 ± 4 % (Fig. S3c) .
The observed extravasation was reduced in comparison to the TS/A tumour model for both the iodinated molecules (range 0.55-0.70, Fig. S3b ) and for gadoteridol (range 0.55 to 0.70, Fig. S3d) .
The correlation of the mean parameters between the two imaging approaches for the 60 matched tumours were moderate for contrast enhancement (r = 0.51, CI: 0.30-0.68, Fig. 3d ) and perfusion (r = 0.56 CI: 0.36-0.71, Fig. 3e ), respectively. The Bland-Altman analysis (Fig. 3f) A different vascularization pattern is evident in the contrast enhancement maps, showing a clear reduction in detection for all the contrast agents when moving from the tumour rim to the tumour core region (Fig. 6 and Fig. S4 ).
The similarity in the distribution of the two classes of agents yields an overall good spatial correspondence between the two MRI-based approaches, in particular in the rim tumour regions that present higher contrast enhancement.
A strong spatial correlation was observed, with mean spatial correlation values for the enhancement maps of 0.72 ± 0.05, 0.79 ± 0.05, and 0.82 ± 0.05 for iodixanol, iohexol, and iopamidol, respectively (Fig. 5d) . The spatial correlation of the extravasation maps between iodinated and gadoteridol molecules was also strong, with mean values of 0.64 ± 0.06, 0.72 ± 0.08, and 0.86 ± 0.07 for iodixanol, iohexol, and iopamidol, respectively (Fig. 5e) . High similarity indexes were observed for all the three investigated molecules: 0.70 ± 0.09, 0.64 ± 0.08, and 0.58 ± 0.09 for iopamidol, iohexol, and iodixanol, respectively (Fig. 5f ). Representative similarity maps with colour-coded pixels are shown in Fig. 6c .
Discussion
To our knowledge, this is the first study comparing MRI-CEST with conventional MRI-CE in the assessment of tumour contrast enhancement and perfusion properties in experimental mouse tumour models. The sequential injection in the same animal of one iodinated CEST agent and one Gd-based agent allows ruling out any bias concerning position and spatial resolution between the two approaches, thus making possible a precise comparison of the parameters obtained by the two techniques. Our study demonstrated that the contrast enhancement values derived from the MRI-CEST approach (with iodinated molecules) is comparable to that derived from MRI-CE (with gadoteridol). In addition, mean tumour perfusion values were significantly correlated and parametric images showed high spatial similarity in two tumour models with different vascularization properties. Therefore, iodinated contrast media within the MRI-CEST modality can represent suitable candidates as alternative agents to Gd-based ones for the in vivo evaluation of tumour properties.
Contrast agents are routinely used to detect tumours either in terms of an enhanced vascularization or in terms of an extensive extravasation [40, 41] . Overall, all the investigated radiographic molecules were able to generate sufficient MRI-CEST contrast to be detected in the tumour region. Iohexol and iopamidol showed comparable contrast enhancement efficiency, in contrast iodixanol showed reduced contrast enhanced values (Fig. 1) . The radiologic efficacy of a contrast agent can be expressed by its increase in signal intensity (enhancement). Gd-based agents provide the highest tumour contrast enhancements, whereas iodinated molecules show a lower degree of enhancement when used within the CT or, as in this work, in the MRI-CEST modality [42] . In this study, the obtained mean tumour contrast enhancement by using iodinated contrast media with the MRI-CEST technique is in the range of 4-10 %. Despite this value is lower of that measured with gadoteridol (60 %), it is still comparable to that attainable in tumour patients using the CT modality with the same agents [43] and higher than what is attainable with biodegradable glucose-based systems [44, 45] . MR imaging is considered superior to CT in tissue characterization because of its superior contrast resolution in both unenhanced and conventional T 1w contrast-enhanced images. On the other hand, the linear relationship between the iodinated CAs concentration and the measured density (in Hounsfield units) are significant advantages of the CT modality that are counterbalanced by limited tissue coverage and radiation burden. Thus, iodinated agents combined with the MRI-CEST technique may be a useful tool for the noninvasive characterization of tumour perfusion, with the advantage that this method does not involve any ionizing radiation exposure.
Tumour tissue is strongly heterogeneous; therefore, the used imaging approach should provide enough spatially resolved resolution for detecting both hypervascular (related to angiogenesis) and hypovascular regions. MRI with Gd-based agents clearly assess the heterogeneous distribution of microcirculation properties, as shown in Figs. 4b and 6b , where areas of high intensity are well detected in the tumour rim. The 4T1 tumour model showed a more heterogeneous vascularization in contrast to the TS/A one, whose vessel distribution is more homogeneous. The particular vascularization pattern for 4T1 tumour model with a strong enhanced tumour rim and a less or not-enhanced tumour core was already been observed elsewhere [46, 47] . Notably, similar information was provided by iodinated contrast media, with areas of higher and lower contrast enhancement that spatially parallel those obtained with gadoteridol (Figs. 4a and 6a) . Though the Pearson's correlation showed a good correlation between MRI-CEST and MRI-CE parameters, it does not take spatial information into account. Therefore, we calculated the spatial correlation for assessing similarity in terms of enhancement and perfusion estimates on a voxel-by-voxel basis upon the sequential injection of the iodinated and Gd-based agents. Interestingly, all the investigated contrast media provided moderate to strong spatial correlation, with iohexol and iopamidol showing higher spatial correlation with parametric maps derived from gadoteridol in comparison to iodixanol. One possible explanation to account for the observed behaviour may be the different molecular weights of the contrast agents, since iodixanol is three times larger than gadoteridol. Concurrently, the higher molecular weight of iodixanol may result in slower wash-in kinetic and tumour accumulation, hence in reduced contrast enhancement.
Another interesting issue is the slightly higher extravasation fraction of gadoteridol (55-90 %) in comparison with that of iodinated contrast media (55-80 %). In principle the enhancement factor of an injected contrast agent inside the tumour pixels is the result of both accumulation and contrast efficiency. Because of its relatively low viscosity, gadoteridol can more easily enter extravascular/extracellular spaces, thus yielding a higher tumour perfusion [48] . Another explanation could be that Gd-based agents possess intrinsic higher contrast efficiency [49] . As a consequence, even small amounts of Gdchelates are sufficient to provide enough contrast Fig. 6 Representative contrast enhanced maps upon (a) i.v. injection of iodinated molecules (iodixanol, iohexol, and iopamidol, from left to right) as MRI-CEST ΔST% maps (calculated as ST% post-injection -ST% pre-injection), followed by i.v. injection of gadoteridol (b) as ΔSI% maps (calculated as (SIpost-injection -SIpre-injection)/SIpre-injection), superimposed onto anatomical T 2w images in 4T1 breast tumours. Example of similarity analysis (c) showing pixels where both iodinated molecules and gadoteridol have been detected (blue pixels) or when only one contrast agent has been detected (red and green, for iodinated or gadoteridol, respectively) enhancements; conversely, iodinated contrast media require sustained accumulation. However, no significant differences were found between the two classes of CAs in terms of extravasation fraction values.
Our study is hampered by some limitations. The wash-in/ wash-out properties of the iodinated contrast agents may affect the gadoteridol-derived estimates due to incomplete differential clearance of the first administered contrast agent. Tentatively, these effects can be ignored, considering that (i) iodinated contrast media are low molecular weight extracellular contrast agents with fast elimination kinetics, (ii) enough time was allowed for the wash-out of the iodinated compounds before gadoteridol injection, and (iii) pre-injection T 1w images were acquired to minimize such confounding effects. This was demonstrated by the fact that the extravasation fraction estimated from the T 1w images was not affected by the order of injection of the contrast agents (Fig. S5) . In fact, no significant differences were observed in the extravasation fraction when gadoteridol was injected before or after iopamidol (P = 0.4). In addition, also the extravasation fraction measured from iopamidol was independent of the contrast agent injection sequence (P = 0.15).
Another important point is that small changes in temperature during the examination may influence tumour physiology, hence the calculated perfusion estimates. However, we observed relatively small changes in temperature between sequential CEST and T 1w image acquisitions (ΔT < 2°C ,  Fig. S6) ; therefore, we can reasonably assume that the perfusion estimates have not been significantly affected.
Reduction in r 1p values at 7 T compared to at lower fields, as those clinically available, could have resulted in lower contrast enhancement values for gadoteridol [50] .
In conclusion, a good correlation between contrast enhanced images obtained using radiographic molecules (MRI-CEST) and gadoteridol (MRI-CE) was found. Voxelwise comparison indicated high spatial distribution similarity of contrast enhancement and perfusion maps. These results demonstrate the potential of MRI-CEST using clinically available X-ray CAs in the set-up of tumour MRI-CE procedures, as those available using conventional Gd-based agents, although further work appear still necessary to improve CEST contrast efficiency.
